Previous 10 | Next 10 |
2023-10-23 08:31:36 ET Losers: Revolution Medicines ( RVMD ) -31% . Troika Media Group ( TRKA ) -21% . Li-Cycle Holdings Corp ( LICY ) -21% announces review of the rochester hub project . Mmtec ( MTC ) -18% . Palatin Technologies ( ...
REDWOOD CITY, Calif., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced promising anti-tumor and safety data for RMC-6236, its RAS MULTI (ON) Inhibitor, in pati...
2023-10-19 14:23:20 ET More on Revolution Medicines Revolution Medicines: A Big Pipeline In Need Of Big Data Revolution Medicines' Strategic Edge In RAS-Driven Oncology Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Call Transcript Why did Revolution Medi...
2023-10-17 14:18:15 ET Are you looking for the best penny stocks to buy now ? Today might be your day…or not. These high-flying, low-priced stocks are well known for their innate ability to explode within a matter of minutes at times. Imagine seeing a stock that trades for pe...
2023-10-16 15:55:39 ET More on Revolution Medicines Revolution Medicines: A Big Pipeline In Need Of Big Data Revolution Medicines' Strategic Edge In RAS-Driven Oncology Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Call Transcript Revolution Medicines st...
2023-10-13 15:00:54 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
2023-10-13 14:54:35 ET Shares of Revolution Medicines (NASDAQ: RVMD) were up more than 20% as of 2 p.m. ET after the company announced positive phase 1/1b trial data for two cancer therapies. The clinical-stage biotech's stock is up more than 22% so far this year. Revolution...
2023-10-13 14:01:47 ET More on Revolution Medicines Revolution Medicines: A Big Pipeline In Need Of Big Data Revolution Medicines' Strategic Edge In RAS-Driven Oncology Revolution Medicines, Inc. (RVMD) Q2 2023 Earnings Call Transcript Revolution Medicines wi...
Clinical dose escalation data for RMC-6236, a RAS MULTI (ON) Inhibitor, show oral bioavailability, well-tolerated safety profile and preliminary evidence of anti-tumor activity across multiple RAS mutations First clinical data presentation for RMC-6291, a RAS G12C ...
Interim Data to be Presented for RMC-6236 (RAS MULTI (ON) Inhibitor) and RMC-6291 (RAS G12C (ON) Inhibitor) Company to Host Investor Webcast Following ESMO Data Presentation on October 22 at 12:30 p.m. Eastern REDWOOD CITY, Calif., Oct. 04, 2023 (GLOBE ...
News, Short Squeeze, Breakout and More Instantly...
Revolution Medicines Inc. Company Name:
RVMD Stock Symbol:
NASDAQ Market:
Revolution Medicines Inc. Website:
2024-07-24 09:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-14 06:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) Re...